{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:23:46Z","timestamp":1792877026004,"version":"4.5.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"1R56DA044302"},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Perinatology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1053\/j.semperi.2019.01.001","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T18:49:12Z","timestamp":1547491752000},"page":"123-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":223,"title":["The United States opioid epidemic"],"prefix":"10.1053","volume":"43","author":[{"given":"Jennifer","family":"Lyden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A.","family":"Binswanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semperi.2019.01.001_bib0001","series-title":"Patient Characteristics of Opioid-Related Inpatient Stays and Emergency Department Visits Nationally and by State, 2014","author":"Weiss","year":"2014"},{"issue":"11","key":"10.1053\/j.semperi.2019.01.001_bib0002","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.2105\/AJPH.2015.302843","article-title":"Worldwide prevalence and trends in unintentional drug overdose: a systematic review of the literature","volume":"105","author":"Martins","year":"2015","journal-title":"Am J Public Health"},{"issue":"26","key":"10.1053\/j.semperi.2019.01.001_bib0003","first-page":"719","article-title":"Vital Signs: demographic and substance use trends among heroin users - United States, 2002-2013","volume":"64","author":"Jones","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1053\/j.semperi.2019.01.001_bib0004","doi-asserted-by":"crossref","first-page":"349","DOI":"10.15585\/mmwr.mm6712a1","article-title":"Overdose deaths involving opioids, cocaine, and psychostimulants \u2014 United States, 2015\u20132016","volume":"67","author":"Seth","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"22","key":"10.1053\/j.semperi.2019.01.001_bib0005","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMp1508818","article-title":"Preventing and treating narcotic addiction \u2014 a century of federal drug control","volume":"373","author":"Courtwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semperi.2019.01.001_bib0006","author":"Trickey"},{"issue":"15","key":"10.1053\/j.semperi.2019.01.001_bib0007","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM188910101211502","article-title":"Substitutes for opium in chronic diseases","volume":"121","year":"1889","journal-title":"Bost Med Surg J"},{"issue":"6","key":"10.1053\/j.semperi.2019.01.001_bib0008","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2105\/AJPH.5.6.518","article-title":"The harrison anti-narcotic act.","volume":"5","author":"Terry","year":"1915","journal-title":"Am J Public Health (N Y)"},{"issue":"26","key":"10.1053\/j.semperi.2019.01.001_bib0009","first-page":"537","article-title":"Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers and other drugs among women\u2013United States, 1999-2010","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1053\/j.semperi.2019.01.001_bib0010","author":"Hui Chen"},{"issue":"8","key":"10.1053\/j.semperi.2019.01.001_bib0011","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2105\/AJPH.2016.303297","article-title":"The ongoing opioid prescription epidemic: historical context","volume":"106","author":"Meldrum","year":"2016","journal-title":"Am J Public Health"},{"issue":"1-2","key":"10.1053\/j.semperi.2019.01.001_bib0012","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1300\/J251v05n01_11","article-title":"American opiophobia: customary underutilization of opioid analgesics","volume":"5","author":"Morgan","year":"1985","journal-title":"Adv Alcohol Subst Abuse"},{"issue":"11","key":"10.1053\/j.semperi.2019.01.001_bib0013","doi-asserted-by":"crossref","first-page":"885","DOI":"10.7326\/0003-4819-113-11-885","article-title":"Improving outcomes of analgesic treatment: is education enough","volume":"113","author":"Max","year":"1990","journal-title":"Ann Intern Med"},{"issue":"Suppl 1(Suppl 1)","key":"10.1053\/j.semperi.2019.01.001_bib0014","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.drugalcdep.2016.12.002","article-title":"Providing chronic pain management in the " Fifth Vital Sign & quot; Era: Historical and treatment perspectives on a modern-day medical dilemma","volume":"173","author":"Tompkins","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"10.1053\/j.semperi.2019.01.001_bib0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/jama.2017.0935","article-title":"History of the joint commission's pain standards","volume":"317","author":"Baker","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"10.1053\/j.semperi.2019.01.001_bib0016","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJM198001103020221","article-title":"Addiction rare in patients treated with narcotics","volume":"302","author":"Porter","year":"1980","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.semperi.2019.01.001_bib0017","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2105\/AJPH.2007.131714","article-title":"The promotion and marketing of oxycontin: commercial triumph, public health tragedy","volume":"99","author":"Van Zee","year":"2009","journal-title":"Am J Public Health"},{"key":"10.1053\/j.semperi.2019.01.001_bib0018","unstructured":"In the United States District Court For The Western District of Virginia Abingdon Division United States of America). http:\/\/i.bnet.com\/blogs\/purdue-agreed-facts.pdf. Accessed September 5, 2018."},{"key":"10.1053\/j.semperi.2019.01.001_bib0019","unstructured":"Purdue and the OxyContin Files | Kaiser Health News. https:\/\/khn.org\/news\/purdue-and-the-oxycontin-files\/. Accessed September 5, 2018."},{"issue":"1113","key":"10.1053\/j.semperi.2019.01.001_bib0020","first-page":"80","article-title":"Oxycodone and oxycontin","volume":"43","year":"2001","journal-title":"Med Lett Drugs Ther"},{"issue":"5","key":"10.1053\/j.semperi.2019.01.001_bib0021","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jpainsymman.2003.03.003","article-title":"Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review","volume":"26","author":"Chou","year":"2003","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"10.1053\/j.semperi.2019.01.001_bib0022","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1592\/phco.22.11.898.33628","article-title":"Safety and efficacy of controlled-release oxycodone: a systematic literature review","volume":"22","author":"Rischitelli","year":"2002","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1053\/j.semperi.2019.01.001_bib0023","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002508-199909000-00004","article-title":"Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain","volume":"15","author":"Hale","year":"1999","journal-title":"Clin J Pain"},{"issue":"11","key":"10.1053\/j.semperi.2019.01.001_bib0024","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/jama.2017.0935","article-title":"History of the joint commission's pain standards","volume":"317","author":"Baker","year":"2017","journal-title":"JAMA"},{"issue":"26","key":"10.1053\/j.semperi.2019.01.001_bib0025","doi-asserted-by":"crossref","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","article-title":"Vital signs: changes in opioid prescribing in the United States, 2006\u20132015","volume":"66","author":"Guy","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"22","key":"10.1053\/j.semperi.2019.01.001_bib0026","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1001\/jama.2008.802","article-title":"Patterns of abuse among unintentional pharmaceutical overdose fatalities","volume":"300","author":"Hall","year":"2008","journal-title":"JAMA"},{"issue":"8","key":"10.1053\/j.semperi.2019.01.001_bib0027","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/pds.1452","article-title":"Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States","volume":"16","author":"Cicero","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1053\/j.semperi.2019.01.001_bib0028","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.drugalcdep.2005.10.020","article-title":"Abuse of prescription drugs and the risk of addiction","volume":"83","author":"Compton","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1053\/j.semperi.2019.01.001_bib0029","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.drugalcdep.2012.11.018","article-title":"National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009","volume":"131","author":"Calcaterra","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1053\/j.semperi.2019.01.001_bib0030","unstructured":"U.S. Prescribing Rate Maps | Drug Overdose | CDC Injury Center. https:\/\/www.cdc.gov\/drugoverdose\/maps\/rxrate-maps.html. Accessed June 18, 2018."},{"key":"10.1053\/j.semperi.2019.01.001_bib0031","author":"Hedegaard"},{"issue":"13","key":"10.1053\/j.semperi.2019.01.001_bib0032","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain \u2014 misconceptions and mitigation strategies.","volume":"374","author":"Volkow","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.semperi.2019.01.001_bib0033","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp021113","article-title":"The neurobiology of opioid dependence: implications for treatment","volume":"1","author":"Kosten","year":"2002","journal-title":"Sci Pract Perspect"},{"key":"10.1053\/j.semperi.2019.01.001_bib0034","author":"Williams"},{"key":"10.1053\/j.semperi.2019.01.001_bib0035","unstructured":"The Science of Drug Abuse and Addiction: The Basics | National Institute on Drug Abuse (NIDA). https:\/\/www.drugabuse.gov\/publications\/media-guide\/science-drug-abuse-addiction-basics. Accessed 20 August 2018."},{"key":"10.1053\/j.semperi.2019.01.001_bib0036","first-page":"991","article-title":"Diagnostic and statistical manual of mental disorders: DSM-5","year":"2013","journal-title":"Am Psychiatr Assoc"},{"issue":"8","key":"10.1053\/j.semperi.2019.01.001_bib0037","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1176\/appi.ajp.2013.12060782","article-title":"DSM-5 criteria for substance use disorders: recommendations and rationale","volume":"170","author":"Hasin","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1053\/j.semperi.2019.01.001_bib0038","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.pain.2011.03.028","article-title":"Prescription opioid analgesics rapidly change the human brain","volume":"152","author":"Younger","year":"2011","journal-title":"Pain"},{"issue":"Pt 7","key":"10.1053\/j.semperi.2019.01.001_bib0039","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/brain\/awq138","article-title":"Alterations in brain structure and functional connectivity in prescription opioid-dependent patients","volume":"133","author":"Upadhyay","year":"2010","journal-title":"Brain"},{"issue":"18","key":"10.1053\/j.semperi.2019.01.001_bib0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.15585\/mmwr.mm6718a5","article-title":"Access to Syringe services programs \u2014 Kentucky, North Carolina, and West Virginia, 2013\u20132017","volume":"67","author":"Bixler","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1053\/j.semperi.2019.01.001_bib0041","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11904-018-0390-3","article-title":"The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: structural-level causes and interventions","volume":"15","author":"Perlman","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1-2","key":"10.1053\/j.semperi.2019.01.001_bib0042","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2010.10.013","article-title":"Initiation and engagement in chronic disease management care for substance dependence","volume":"115","author":"Kim","year":"2011","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1053\/j.semperi.2019.01.001_bib0043","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/ADM.0b013e318166af74","article-title":"The case for chronic disease management for addiction","volume":"2","author":"Saitz","year":"2008","journal-title":"J Addict Med"},{"issue":"7","key":"10.1053\/j.semperi.2019.01.001_bib0044","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/phar.1954","article-title":"Neonatal abstinence syndrome: update on diagnostic and therapeutic strategies","volume":"37","author":"Raffaeli","year":"2017","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"1","key":"10.1053\/j.semperi.2019.01.001_bib0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1940-0640-9-19","article-title":"Review of the assessment and management of neonatal abstinence syndrome","volume":"9","author":"Bagley","year":"2014","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"10.1053\/j.semperi.2019.01.001_bib0046","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1542\/peds.2013-3524","article-title":"Neonatal abstinence syndrome","volume":"134","author":"Kocherlakota","year":"2014","journal-title":"Pediatrics"},{"issue":"7","key":"10.1053\/j.semperi.2019.01.001_bib0047","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jama.2018.7820","article-title":"Stigmatizing language about neonatal abstinence syndrome","volume":"320","author":"Shapiro","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1053\/j.semperi.2019.01.001_bib0048","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1471-0528.2008.02073.x","article-title":"Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources","volume":"116","author":"Dryden","year":"2009","journal-title":"BJOG"},{"issue":"3","key":"10.1053\/j.semperi.2019.01.001_bib0049","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000210042","article-title":"Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study","volume":"15","author":"Bakstad","year":"2009","journal-title":"Eur Addict Res"},{"issue":"1","key":"10.1053\/j.semperi.2019.01.001_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2008.08.041","article-title":"High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome","volume":"200","author":"Lim","year":"2009","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"10.1053\/j.semperi.2019.01.001_bib0051","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/j.1360-0443.2010.03120.x","article-title":"Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis","volume":"105","author":"Cleary","year":"2010","journal-title":"Addiction"},{"issue":"24","key":"10.1053\/j.semperi.2019.01.001_bib0052","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semperi.2019.01.001_bib0053","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006318.pub3","article-title":"Maintenance agonist treatments for opiate-dependent pregnant women","author":"Minozzi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.semperi.2019.01.001_bib0054","unstructured":"Results from the 2016 National Survey on Drug Use and Health. https:\/\/www.samhsa.gov\/sites\/default\/files\/sites\/default\/files\/2016_ffr_1_slideshow_v5.pdf. Accessed July 22, 2018."},{"issue":"34","key":"10.1053\/j.semperi.2019.01.001_bib0055","doi-asserted-by":"crossref","first-page":"897","DOI":"10.15585\/mmwr.mm6634a2","article-title":"Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region \u2014 United States, 2006\u20132015","volume":"66","author":"O'Donnell","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1053\/j.semperi.2019.01.001_bib0056","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.annepidem.2013.05.017","article-title":"Increasing pregnancy-related use of prescribed opioid analgesics","volume":"23","author":"Epstein","year":"2013","journal-title":"Ann Epidemiol"},{"issue":"5","key":"10.1053\/j.semperi.2019.01.001_bib0057","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/AOG.0000000000000208","article-title":"Increase in prescription opioid use during pregnancy among medicaid-enrolled women","volume":"123","author":"Desai","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1053\/j.semperi.2019.01.001_bib0058","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/ALN.0000000000000172","article-title":"Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States","volume":"120","author":"Bateman","year":"2014","journal-title":"Anesthesiology"},{"issue":"7","key":"10.1053\/j.semperi.2019.01.001_bib0059","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1053\/j.semperi.2015.08.013","article-title":"Opioids in pregnancy and neonatal abstinence syndrome","volume":"39","author":"Stover","year":"2015","journal-title":"Semin Perinatol"},{"issue":"31","key":"10.1053\/j.semperi.2019.01.001_bib0060","doi-asserted-by":"crossref","first-page":"845","DOI":"10.15585\/mmwr.mm6731a1","article-title":"Opioid use disorder documented at delivery hospitalization \u2014 United States, 1999\u20132014","volume":"67","author":"Haight","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"10.1053\/j.semperi.2019.01.001_bib0062","doi-asserted-by":"crossref","first-page":"242","DOI":"10.15585\/mmwr.mm6609a2","article-title":"CDC grand rounds: public health strategies to prevent neonatal abstinence syndrome","volume":"66","author":"Ko","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1053\/j.semperi.2019.01.001_bib0063","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/jp.2015.36","article-title":"Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012","volume":"35","author":"Patrick","year":"2015","journal-title":"J Perinatol"},{"issue":"9","key":"10.1053\/j.semperi.2019.01.001_bib0064","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/add.13842","article-title":"The economic burden of neonatal abstinence syndrome in the United States","volume":"112","author":"Corr","year":"2017","journal-title":"Addiction"},{"issue":"3","key":"10.1053\/j.semperi.2019.01.001_bib0065","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08897077.2014.930372","article-title":"Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response","volume":"35","author":"Broyles","year":"2014","journal-title":"Subst Abus"},{"issue":"14","key":"10.1053\/j.semperi.2019.01.001_bib0066","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jama.2014.2147","article-title":"Confronting the stigma of opioid use disorder\u2014and its treatment","volume":"311","author":"Olsen","year":"2014","journal-title":"JAMA"},{"key":"10.1053\/j.semperi.2019.01.001_bib0067","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.drugalcdep.2018.05.005","article-title":"Substance use, recovery, and linguistics: the impact of word choice on explicit and implicit bias","volume":"189","author":"Ashford","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1053\/j.semperi.2019.01.001_bib0068","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugpo.2009.10.010","article-title":"Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms","volume":"21","author":"Kelly","year":"2010","journal-title":"Int J Drug Policy"},{"key":"10.1053\/j.semperi.2019.01.001_bib0069","doi-asserted-by":"crossref","unstructured":"Kelly JF, Saitz R, Wakeman S. Alcoholism Treatment Quarterly Language, Substance Use Disorders, and Policy: The Need to Reach Consensus on an "Addiction-ary" 2016. doi:10.1080\/07347324.2016.1113103doi.org\/10.1080\/07347324.2016.1113103.","DOI":"10.1080\/07347324.2016.1113103"},{"issue":"9","key":"10.1053\/j.semperi.2019.01.001_bib0070","doi-asserted-by":"crossref","DOI":"10.1176\/appi.pn.2018.5a24","article-title":"Final words","volume":"53","author":"Everett","year":"2018","journal-title":"Psychiatr News"},{"issue":"1","key":"10.1053\/j.semperi.2019.01.001_bib0071","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1940-0640-7-10","article-title":"Just call it \u201ctreatment.\u201d","volume":"7","author":"Friedmann","year":"2012","journal-title":"Addict Sci Clin Pract"},{"issue":"5","key":"10.1053\/j.semperi.2019.01.001_bib0072","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.amjmed.2015.12.028","article-title":"Using science to battle stigma in addressing the opioid epidemic: opioid agonist therapy saves lives","volume":"129","author":"Wakeman","year":"2016","journal-title":"Am J Med"},{"issue":"1","key":"10.1053\/j.semperi.2019.01.001_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ADM.0000000000000275","article-title":"Medications for addiction treatment","volume":"11","author":"Wakeman","year":"2017","journal-title":"J Addict Med"},{"issue":"2","key":"10.1053\/j.semperi.2019.01.001_bib0074","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.semperi.2019.01.001_bib0075","unstructured":"U.S. Prescribing Rate Maps | Drug Overdose | CDC Injury Center. https:\/\/www.cdc.gov\/drugoverdose\/maps\/rxrate-maps.html. Accessed August 25, 2018."},{"issue":"9","key":"10.1053\/j.semperi.2019.01.001_bib0076","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/pds.1276","article-title":"Increasing deaths from opioid analgesics in the United States","volume":"15","author":"Paulozzi","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1053\/j.semperi.2019.01.001_bib0077","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2105\/AJPH.2005.071647","article-title":"Opioid analgesic involvement in drug abuse deaths in American metropolitan areas","volume":"96","author":"Paulozzi","year":"2006","journal-title":"Am J Public Health"},{"issue":"2","key":"10.1053\/j.semperi.2019.01.001_bib0078","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-152-2-201001190-00006","article-title":"Opioid prescriptions for chronic pain and overdose","volume":"152","author":"Dunn","year":"2010","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1053\/j.semperi.2019.01.001_bib0079","doi-asserted-by":"crossref","DOI":"10.1001\/archinternmed.2011.117","article-title":"Opioid dose and drug-related mortality in patients with nonmalignant pain","volume":"171","author":"Gomes","year":"2011","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1053\/j.semperi.2019.01.001_bib0080","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/jamainternmed.2014.8071","article-title":"Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy","volume":"175","author":"Miller","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"13","key":"10.1053\/j.semperi.2019.01.001_bib0081","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jama.2011.370","article-title":"Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths","volume":"305","author":"Bohnert","year":"2011","journal-title":"JAMA"},{"key":"10.1053\/j.semperi.2019.01.001_bib0082","doi-asserted-by":"crossref","first-page":"h2698","DOI":"10.1136\/bmj.h2698","article-title":"Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study","volume":"350","author":"Park","year":"2015","journal-title":"BMJ"},{"key":"10.1053\/j.semperi.2019.01.001_bib0083","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-017-4288-3","article-title":"Prediction model for two-year risk of opioid overdose among patients prescribed chronic opioid therapy","author":"Glanz","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"1","key":"10.1053\/j.semperi.2019.01.001_bib0084","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic Pain \u2014 United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Reports"},{"issue":"7","key":"10.1053\/j.semperi.2019.01.001_bib0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1526-4637.2012.01412.x","article-title":"Influencing controlled substance prescribing: attending and resident physician use of a state prescription monitoring program","volume":"13","author":"Feldman","year":"2012","journal-title":"Pain Med"},{"key":"10.1053\/j.semperi.2019.01.001_bib0087","unstructured":"Prescription Drug Monitoring Program Center of Excellence at Brandeis Briefing on PDMP Effectiveness. www.pdmpexcellence.org. Accessed August 26, 2018."},{"issue":"7","key":"10.1053\/j.semperi.2019.01.001_bib0088","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1377\/hlthaff.2015.1496","article-title":"Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates","volume":"35","author":"Patrick","year":"2016","journal-title":"Health Aff"},{"issue":"6","key":"10.1053\/j.semperi.2019.01.001_bib0089","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/00952990.2010.505991","article-title":"Heroin anticraving medications: a systematic review","volume":"36","author":"Fareed","year":"2010","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"4","key":"10.1053\/j.semperi.2019.01.001_bib0090","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semperi.2019.01.001_bib0091","series-title":"Cochrane Database of Systematic Reviews","article-title":"Oral naltrexone maintenance treatment for opioid dependence","author":"Minozzi","year":"2011"},{"issue":"9776","key":"10.1053\/j.semperi.2019.01.001_bib0092","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1053\/j.semperi.2019.01.001_bib0093","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archgenpsychiatry.2012.1a","article-title":"Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence","volume":"69","author":"Krupitsky","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1053\/j.semperi.2019.01.001_bib0094","article-title":"Review of case narratives from fatal overdoses associated with injectable naltrexone for opioid dependence","author":"Saucier","year":"2018","journal-title":"Drug Saf"},{"issue":"August","key":"10.1053\/j.semperi.2019.01.001_bib0095","article-title":"Potential risk window for opioid overdose related to treatment with extended-release injectable naltrexone","author":"Binswanger","year":"2018","journal-title":"Drug Saf"},{"issue":"2","key":"10.1053\/j.semperi.2019.01.001_bib0096","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatr Serv"},{"issue":"2","key":"10.1053\/j.semperi.2019.01.001_bib0097","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1176\/appi.ps.201300235","article-title":"Medication-assisted treatment with methadone: assessing the evidence","volume":"65","author":"Fullerton","year":"2014","journal-title":"Psychiatr Serv"},{"issue":"5","key":"10.1053\/j.semperi.2019.01.001_bib0098","article-title":"Opioid agonist treatment for pharmaceutical opioid dependent people","author":"Nielsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1053\/j.semperi.2019.01.001_bib0099","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1053\/j.semperi.2019.01.001_bib0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2471\/BLT.12.108282","article-title":"Mortality among people who inject drugs: a systematic review and meta-analysis","volume":"91","author":"Mathers","year":"2013","journal-title":"Bull World Health Organ"},{"issue":"1-2","key":"10.1053\/j.semperi.2019.01.001_bib0101","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2009.05.021","article-title":"Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved","volume":"105","author":"Degenhardt","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1053\/j.semperi.2019.01.001_bib0102","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1053\/j.semperi.2019.01.001_bib0103","unstructured":"DEA Requirements for DATA Waived Physicians (DWPs). https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/dwp_buprenorphine.htm. Accessed August 22, 2018."},{"issue":"8","key":"10.1053\/j.semperi.2019.01.001_bib0104","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"Am J Public Health"},{"issue":"June","key":"10.1053\/j.semperi.2019.01.001_bib0105","article-title":"Geographic Distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update","author":"Andrilla","year":"2018","journal-title":"J Rural Heal"},{"key":"10.1053\/j.semperi.2019.01.001_bib0106","unstructured":"Substance Use During Pregnancy | Guttmacher Institute. https:\/\/www.guttmacher.org\/state-policy\/explore\/substance-use-during-pregnancy. Accessed July 22, 2018."},{"key":"10.1053\/j.semperi.2019.01.001_bib0107","unstructured":"Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants ii Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants. http:\/\/store.samhsa.gov. Accessed July 6, 2018."},{"issue":"3","key":"10.1053\/j.semperi.2019.01.001_bib0108","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jsat.2007.10.007","article-title":"Treatment of opioid-dependent pregnant women: Clinical and research issues","volume":"35","author":"Jones","year":"2008","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"10.1053\/j.semperi.2019.01.001_bib0109","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/ADM.0000000000000289","article-title":"Medically assisted withdrawal (Detoxification)","volume":"11","author":"Jones","year":"2017","journal-title":"J Addict Med"},{"issue":"3","key":"10.1053\/j.semperi.2019.01.001_bib0110","doi-asserted-by":"crossref","first-page":"402","DOI":"10.2105\/AJPH.2008.136937","article-title":"Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality","volume":"99","author":"Kim","year":"2009","journal-title":"Am J Public Health"},{"issue":"2","key":"10.1053\/j.semperi.2019.01.001_bib0111","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/08897077.2015.1010032","article-title":"A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice","volume":"36","author":"Mueller","year":"2015","journal-title":"Subst Abus"},{"key":"10.1053\/j.semperi.2019.01.001_bib0112","doi-asserted-by":"crossref","first-page":"f174","DOI":"10.1136\/bmj.f174","article-title":"Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis","volume":"346","author":"Walley","year":"2013","journal-title":"BMJ"},{"issue":"3","key":"10.1053\/j.semperi.2019.01.001_bib0113","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/ADM.0000000000000034","article-title":"A systematic review of community opioid overdose prevention and naloxone distribution programs","volume":"8","author":"Clark","year":"2014","journal-title":"J Addict Med"},{"issue":"4","key":"10.1053\/j.semperi.2019.01.001_bib0114","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/ajad.12384","article-title":"Incorporation of poison center services in a state-wide overdose education and naloxone distribution program","volume":"25","author":"Doyon","year":"2016","journal-title":"Am J Addict"},{"issue":"1","key":"10.1053\/j.semperi.2019.01.001_bib0115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1471-2458-14-297","article-title":"Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study","volume":"14","author":"Doe-Simkins","year":"2014","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1053\/j.semperi.2019.01.001_bib0116","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.drugpo.2009.01.003","article-title":"Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA","volume":"21","author":"Wagner","year":"2010","journal-title":"Int J Drug Policy"},{"key":"10.1053\/j.semperi.2019.01.001_bib0117","unstructured":"HHS, Samhsa, Capt. Samhsa's Center for the Application of Prevention Technologies Preventing the Consequences of Opioid Overdose: Understanding Naloxone Access Laws. https:\/\/www.samhsa.gov\/capt\/. Accessed July 22, 2018."}],"container-title":["Seminars in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146000519300011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146000519300011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:54:33Z","timestamp":1758938073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146000519300011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0146000519300011"],"URL":"https:\/\/doi.org\/10.1053\/j.semperi.2019.01.001","relation":{},"ISSN":["0146-0005"],"issn-type":[{"value":"0146-0005","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The United States opioid epidemic","name":"articletitle","label":"Article Title"},{"value":"Seminars in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semperi.2019.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}